Loading…

Loading grant details…

Active HORIZON European Commission

How do drug-associated contexts drive behaviour? The role of entorhinal circuitry in addiction

€1.5M EUR

Funder European Commission
Recipient Organization Universitatsklinikum Heidelberg
Country Germany
Start Date Jan 01, 2024
End Date Dec 31, 2028
Duration 1,826 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101117791
Grant Description

Addiction to drugs is a ubiquitous neuropathological disease that inflicts immense societal costs.

A core aspect of addiction that poses a major challenge for treatment is the propensity to relapse in environmental contexts that are associated with drug use.

Identification and mechanistic characterization of novel addiction-relevant circuitry linking the motivation to take drugs to the complex spatial and non-spatial features that constitute a drug-associated context are at the core of this proposal.

These insights will be used to identify the best constellation of anatomical targets to prevent and reverse the expression of context-triggered drug-seeking.

The medial and lateral entorhinal cortex (MEC and LEC) are two central components of the episodic memory system integrating all features relevant for the formation of contextual memory.

Crucially, MEC and LEC receive strong bottom-up dopaminergic input from the midbrain and send top-down projections to the nucleus accumbens (NAc). The dopaminergic system is the primary target of all addictive drugs.

We will 1) study how bottom-up dopaminergic projections are implemented into drug-context associations in MEC and LEC and 2) determine how these associations influence NAc-mediated drug-seeking behaviour.

We will utilize a multidisciplinary approach by developing electrophysiological in vivo recording paradigms in behaving mice that allow the assessment of complex spatial, contextual and non-spatial codes in conditioned place preference and self-administration paradigms typically used to model addiction in rodents.

This will be combined with optogenetically-assisted circuit analysis of molecularly-defined pathways to link identified functions to the underlying circuitry.

Pathway-specific optogenetic silencing will be used to prevent and reverse the manifestations of drug use on a neuronal and behavioural level. This will guide the evidence-based development of therapies in the future, such as deep-brain stimulation.

All Grantees

Universitatsklinikum Heidelberg

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant